SCHEMBL2467031

SCHEMBL2467031

O=C(O)N1CCC(n2cc(-c3ccc(Cl)c(Cl)c3)c3cnccc32)CC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 8/20 0.42
KCNH2 Q12809 5/20 0.42
GSK3B P49841 4/20 0.42
TBXA2R P21731 1/20 0.40
PTGDR Q13258 1/20 0.40
SLC22A12 Q96S37 1/20 0.39
BTK Q06187 6/20 0.37
BLK P51451 1/20 0.37
EGFR P00533 1/20 0.36
LCK P06239 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM1A O60341 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2464730 0.89 DYRK1A (0.41) DYRK1AKCNH2GSK3BTBXA2RPTGDR
SCHEMBL2464307 0.89 DYRK1A (0.43) DYRK1AKCNH2GSK3BSLC22A12BTK
SCHEMBL12327130 0.86 PRKCG (0.47) SLC22A12BTKEGFR
SCHEMBL27908150 0.83 SLC22A12 (0.40) DYRK1AKCNH2GSK3BTBXA2RPTGDR
SCHEMBL12326458 0.82 CHRNB2 (0.43) DYRK1AKCNH2GSK3B
Hydrochloric Acid SCHEMBL2430559 0.81 CHRNB2 (0.42) DYRK1AKCNH2GSK3B
SCHEMBL14875621 0.77 IKBKB (0.40) DYRK1AKCNH2GSK3BBTKBLK
SCHEMBL12327702 0.75 PRKCG (0.49) BTKEGFRHPGD
SCHEMBL18976877 0.73 DYRK1A (0.46) DYRK1AKCNH2GSK3B
SCHEMBL27926310 0.71 DYRK1A (0.39) DYRK1AKCNH2GSK3BSLC22A12BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9227967-B2 Inhibitor compounds of semicarbazide-sensitive amine oxidases PROXIMAGEN LIMITED (GB) 2016-01-05 US disclosed
EP-2927233-A1 INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE Proximagen Limited (GB) 2015-10-07 EP disclosed
EP-2547677-B1 INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE PROXIMAGEN LTD (GB) 2015-05-06 EP disclosed
US-20130102587-A1 New Enzyme Inhibitor Compounds PROXIMAGEN LIMITED (GB) 2013-04-25 US disclosed
EP-2547677-A2 INHIBITORS OF SEMICARABAZIDE - SENSITIVE AMINE OXIDASE Proximagen Limited (GB) 2013-01-23 EP disclosed
WO-2011113798-A2 NEW ENZYME INHIBITOR COMPOUNDS PROXIMAGEN LIMITED (GB) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102587-A1 New Enzyme Inhibitor Compounds SERPINB1, SSB, NFKBIA DYRK1A 4354/4885KCNH2 4480/4885GSK3B 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.